Skip to main content

Pharma/Regulatory

EULAR 2023 – Day 2 Report

Jun 01, 2023

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial

Read Article
Always great to have @EMA_News to come and to talk to us at #EULAR2023 Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍 @RheumNow https://t.co/hSutraUsFD

EULAR 2023: Featured Industry Presentations

May 30, 2023

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR 2023

Read Article

Belimumab in Lupus Nephritis

May 29, 2023

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.



A meta-analysis and systematic review of six

Read Article

3-4-5 Rule (5.26.2023)

May 26, 2023

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

May 25, 2023

Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA). This has implications on diagnosis and population care.  A recent analysis of Norway registry data answers this

Read Article

Falls with Knee Osteoarthritis

May 24, 2023

A study of adults aged 45-85 yrs shows that knee osteoarthritis (OA) is an independent risk factor for falls, suggesting a greater need for awareness and prevention.



Data were derived from a 3 year Canadian Longitudinal (Survey) Study on Aging examing those with reported knee OA or no

Read Article

NSAID Prescribing Decreasing

May 24, 2023

Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.



This systematic review looked at osteoarthritis patients and non-steroidal anti-inflammatory drugs (NSAIDs) use. A total of

Read Article

How Age of Onset Affects Giant Cell Arteritis

MedPage Today
May 23, 2023

Giant cell arteritis (GCA) has a different phenotype when diagnosed late in life compared with earlier onset, a large Italian cohort study indicated.



Features of what might be called "senior GCA" include increased rates of cranial symptoms, a markedly higher risk for aortic aneurysm

Read Article

Allergic Drug-Induced Arthritis (5.19.2023)

May 19, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.




  1. Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK

Read Article

Peresolimab's Potential in Rheumatoid Arthritis

May 18, 2023

Peresolimab is a humanized IgG1 monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active rheumatoid arthritis (RA). 

Read Article

MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor

May 17, 2023

A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.

Read Article

Brepocitinib in Active Psoriatic Arthritis

May 17, 2023

Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.



Brepocitinib is an oral, selective Tyk2/JAK1 inhibitor with both

Read Article

Evidence-Based Guidelines for EGPA

May 16, 2023

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally. This adult disorder has a mean age at diagnosis of nearly 50 years and affects both sexes equally,

Read Article

RELIEF Trial: Sublingual Cyclobenzaprine in Fibromyalgia

MedPage Today
May 16, 2023

Fibromyalgia patients hoping to see a more effective and convenient formulation of cyclobenzaprine at their local pharmacies must wait for an ongoing phase III trial -- the product's third -- to finish, as the first two delivered mixed results.

Read Article

Juvenile and Adult-onset Scleroderma Differ

May 15, 2023

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.  

Read Article
2010 Colchicine Price Hikes Adversely Affected Gout Care Research shows that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use,. https://t.co/WS721SlM6p https://t.co/BBdqDVGolq

Orphan drugs target rare dz <200k. New drugs (2008-2016) compared 5 yr sales 86 orphan Rx to 232 non-orphan = similar sales- Orphan ($719 mill) vs nonorphan ($812 mill). But orphan Rx lower volume offset by higher prices (7X higher) than nonorphan drugs https://t.co/I8kb4A0eyG https://t.co/gEQpssRVkg

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

May 12, 2023

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients. The use of newer b/tsDMARD was hampered by limited

Read Article

One in Ten is Bad! (5.12.2023)

May 12, 2023

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Read Article

2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections

May 11, 2023

Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised. A EULAR task force has established recommendations for screening and prophylaxis against OI. 

Read Article

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis

May 11, 2023

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).



Previous studies have shown an increased risk of VTE in DM patients, usually within 2 years of onset. Moreover, the FDA has recently

Read Article

2010 Colchicine Price Hikes Adversely Affected Gout Care

May 10, 2023

Researchers from Harvard have reported their analysis showing that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use, with a 10 year increase in emergency department and rheumatology gout visits suggesting poorer gout

Read Article

National Population Insights (4.28.2023)

Apr 28, 2023

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article

Denosumab Reduces Type II Diabetes Risk

Apr 25, 2023

The British Medical Journal has publish a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of incident type 2 diabetes (NIDDM) compared with those taking oral bisphosphonates for osteoporosis.



Design Population based study involving emulation of a

Read Article
×